Atara Biotherapeutics Inc (ATRA)
NASDAQ:ATRA
Want to see ATRA full AI Analyst Report?
ATRA Stock Chart & Stats
$15.79
-$1.12(-6.68%)
At close: 4:00 PM EST
$15.79
-$1.12(-6.68%)
Day’s Range― - ―
52-Week Range$3.92 - $19.15
Previous CloseN/A
Volume32.09K
Average Volume (3M)2.87M
Market Cap
$90.73M
Enterprise Value$88.86M
Total Cash (Recent Filing)$8.36M
Total Debt (Recent Filing)$10.09M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Aug 10, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding9,010,172
10 Day Avg. Volume91,707
30 Day Avg. Volume2,866,203
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.89
Price to Sales (P/S)1.88
P/FCF Ratio-4.45
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue3.84
Enterprise Value/Gross Profit4.00
Enterprise Value/Ebitda-16.21
Forecast
1Y Price Target
$13.67Price Target Upside-13.45% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.3
Revenue Forecast (FY)$7.77M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~96% trailing gross margin implies structurally attractive unit economics for Atara's biologics and collaboration revenue. High product-level margins support strong operating leverage upon commercialization or royalty streams, enhancing long-term profitability potential even as R&D costs persist.
Clearer FDA Path For Tab-celRegulatory clarity from the FDA that a well‑designed single‑arm study with historical controls may be sufficient materially reduces approval uncertainty for tab-cel. This durable change lowers clinical development risk, enables a focused resubmission pathway, and increases the likelihood of future approval-driven revenue events.
Strategic Partnership With Pierre FabreHaving Pierre Fabre lead the resubmission leverages partner development and commercialization capabilities, reducing Atara's cash and execution burden. Durable partnership alignment creates defined milestone and royalty channels, improving capital efficiency and de-risking go-to-market responsibilities for key assets.
Bears Say
Negative Shareholder EquityPersistently negative equity reflects cumulative losses that impair the company's capital structure. This durable solvency signal constrains borrowing capacity, raises financing costs, and increases the probability of dilutive capital raises, limiting financial flexibility until profitability or capital restoration occurs.
Persistent Cash BurnSustained negative operating and free cash flow (~-$25.9M TTM) demonstrates a structural funding gap. Ongoing burn forces reliance on external financing or partner funding, heightening dilution risk and constraining the firm's ability to advance multiple programs or scale operations without securing additional capital.
Nasdaq Listing Non-compliance RiskA Nasdaq non‑compliance notice is a persistent corporate governance and liquidity risk. Delisting or transfer to a lower tier would reduce market visibility, hurt institutional access, and make future equity raises costlier, creating lasting frictions to capital formation and investor base stability until resolved.
Atara Biotherapeutics News
ATRA FAQ
What was Atara Biotherapeutics Inc’s price range in the past 12 months?
Atara Biotherapeutics Inc lowest stock price was $3.92 and its highest was $19.14 in the past 12 months.
What is Atara Biotherapeutics Inc’s market cap?
Atara Biotherapeutics Inc’s market cap is $90.73M.
When is Atara Biotherapeutics Inc’s upcoming earnings report date?
Atara Biotherapeutics Inc’s upcoming earnings report date is Aug 10, 2026 which is in 50 days.
How were Atara Biotherapeutics Inc’s earnings last quarter?
Atara Biotherapeutics Inc released its earnings results on May 12, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.33 by $0.04.
Is Atara Biotherapeutics Inc overvalued?
According to Wall Street analysts Atara Biotherapeutics Inc’s price is currently Overvalued.
Does Atara Biotherapeutics Inc pay dividends?
Atara Biotherapeutics Inc does not currently pay dividends.
What is Atara Biotherapeutics Inc’s EPS estimate?
Atara Biotherapeutics Inc’s EPS estimate is -0.32.
How many shares outstanding does Atara Biotherapeutics Inc have?
Atara Biotherapeutics Inc has 9,010,172 shares outstanding.
What happened to Atara Biotherapeutics Inc’s price movement after its last earnings report?
Atara Biotherapeutics Inc reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.33. Following the earnings report the stock price went up 6.83%.
Which hedge fund is a major shareholder of Atara Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ATRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atara Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.67 (-13.45% Downside)
$13.67 (-13.45% Downside)
Hedge Fund Trend
Decreased
By 70.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.56%
12-Months-Change
Fundamentals
Return on Equity
25.68%
Trailing 12-Months
Asset Growth
-67.77%
Trailing 12-Months
Company Description
Atara Biotherapeutics Inc
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
ATRA Stock 12 Month Forecast
Average Price Target
$13.67
▼(-13.45% Downside)
Technical Analysis
Ownership Overview
48.91% Insiders
5.47% Mutual Funds
18.18% Other Institutional Investors
24.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---